[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100600151":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":40,"collaborators":42,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":10,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":10,"enrollmentInfo":54,"targetDuration":10,"studyType":57,"phases":10,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":66,"whyStopped":10,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Fuzhou General Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment-naive patients with advanced SMARCA4-mutated NSCLC",null,"1. Patients pathologically confirmed as having NSCLC, with histologically or cytologically confirmed unresectable locally advanced (Stage IIIB\u002FIIIC) that is not amenable to curative-intent concurrent chemoradiotherapy, metastatic, or recurrent (Stage IV) non-squamous NSCLC, staged according to the IASLC 9th Edition Lung Cancer TNM Staging System by the International Association for the Study of Lung Cancer and the Union for International Cancer Control;\n2. Confirmed SMARCA4 mutation (by NGS testing);\n3. ECOG PS 0-1, with no prior systemic therapy;\n4. Absence of driver gene mutations such as EGFR, ALK, or ROS1;\n5. Patients who can provide sufficient blood samples (see sample requirements for details) and complete basic clinical data, including age, gender, smoking history, family history, lesion location(s), lesion size(s), number of lesions, tumor markers, pathological indicators, treatment information, and re-examination\u002Ffollow-up information;\n6. Voluntary participation wi",[13],"Drug: Atezolizumab+Bevacizumab+Carboplatin+Paclitaxel",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","Atezolizumab+Bevacizumab+Carboplatin+Paclitaxel","Atezolizumab: 1200 mg IV every 3 weeks; Bevacizumab: 15 mg\u002Fkg IV every 3 weeks; Carboplatin: AUC 5 IV every 3 weeks; Paclitaxel: 175 mg\u002Fm² IV every 3 weeks. Treatment cycles: After 4-6 cycles, continue Atezolizumab + Bevacizumab as maintenance therapy until disease progression or unacceptable toxicity.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Zongyang Yu","CONTACT","13509327806","yuzy527@sina.com",[27],{"facility":28,"status":10,"city":29,"state":10,"zip":10,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"The 900th Hospital of the Joint Logistic Support Force, PLA, Fuzhou, Fujian, China, 350025","Fuzhou","China","CN",{"type":33,"coordinates":34},"Point",[35,36],119.30611,26.06139,{"lat":36,"lon":35},[39],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},{"type":41,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[43],{"name":44,"class":6},"900th Hospital of PLA Joint Logistic Support Force","100600151","efficacy-and-safety-analysis-of-first-line-abcp-therapy-in-advanced-smarca4-mutated-nsclc-100600151",false,"NCT07093762","Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC","Efficacy and Safety Analysis of First-Line ABCP Four-Drug Combination Therapy in Advanced SMARCA4-Mutated Non-Small Cell Lung Cancer: A Multicenter, Single-Arm, Prespecified Subgroup Clinical Trial","Inclusion Criteria:\n\n1. Patients with pathologically confirmed NSCLC, meeting the following criteria based on the IASLC 9th Edition Lung Cancer TNM Staging System (International Association for the Study of Lung Cancer\u002FUnion for International Cancer Control): Histologically or cytologically confirmed unresectable locally advanced (Stage IIIB\u002FIIIC) disease not amenable to curative-intent concurrent chemoradiotherapy, metastatic, or recurrent (Stage IV) non-squamous NSCLC;\n2. Confirmed SMARCA4 mutation (verified by NGS testing);\n3. ECOG performance status 0-1, with no prior systemic anticancer therapy;\n4. Absence of driver gene mutations (e.g., EGFR, ALK, ROS1);\n5. Patients capable of providing sufficient blood samples (detailed in sample requirements) and complete baseline clinical data, including: age, gender, smoking history, family history, lesion location(s), lesion size(s), number of lesions, tumor markers, pathological indicators, treatment records, and re-examination\u002Ffollow-up information;\n6. Voluntary participation with signed informed consent form, willingness to undergo follow-up assessments and provide treatment process details, efficacy data, and prognostic information, with commitment to complete the entire study.\n\nExclusion Criteria:\n\n* (1) Active autoimmune diseases or interstitial lung disease; (2) Bleeding tendency or contraindications to Bevacizumab.","ALL","18 Years",{"count":55,"type":56},35,"ESTIMATED","OBSERVATIONAL","SMARCA4 mutation is clinically known to be an independent poor prognostic factor. Both TCGA and the investigators institution's preliminary research indicate that the median overall survival (OS) of mutated patients is significantly shorter than that of wild-type patients (32 months vs. 157.7 months, respectively, P=0.001); it is associated with chemotherapy\u002Fimmunotherapy resistance, rapid progression, and poor prognosis (OS\\\u003C12 months). Current standard first-line treatments (such as platinum-based chemotherapy ± immunotherapy) have limited efficacy in SMARCA4-mutated patients (ORR\\\u003C30%, PFS\\\u003C4 months). Additionally, NapsinA-positive expression can improve the survival of mutated patients (median OS: 32 months vs. 15 months, P=0.033), but this effect exists only in the SMARCA4-mutated group.\n\nThe ABCP regimen has a synergistic mechanism: Atezolizumab (anti-PD-L1): reverses the immunosuppressive microenvironment; Bevacizumab (anti-VEGF): inhibits angiogenesis and enhances T-cell infiltration; Platinum + Paclitaxel: directly kill tumor cells and release neoantigens. Therefore, the investigators preset that SMARCA4 mutation may affect chemotherapy\u002Fimmunotherapy response through epigenetic regulation, and its value as a predictive biomarker needs to be validated. Hence, the purpose of this study is to observe and explore the efficacy and safety of first-line ABCP four-drug combination therapy in patients with advanced SMARCA4-mutated non-small cell lung cancer.",[60],"Non Small Cell Lung Cancer",[62,63,64,65],"SMARCA4","NSCLC","treatment efficacy","biomarker","NOT_YET_RECRUITING","2025-07-22",{"date":69,"type":70},"2025-07-30","ACTUAL",{"date":72,"type":56},"2025-08-20",{"date":74,"type":56},"2028-06-30",{"name":5,"class":6},1]